CDCaitlin H. Daly

Caitlin H. Daly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caitlin H. Daly has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma

    by Wee Joo Chng, David Bin-Chia Wu, Cathy Kwang-Wei Wu, Aaron Springford, Caitlin H Daly, Sung-Hoon Jung

  • Open Access

    Generalized Fused Lasso for Treatment Pooling in Network Meta‐Analysis

    by Xiangshan Kong, Caitlin H. Daly, Audrey Béliveau

    This work develops a generalized fused lasso (GFL) approach to fitting contrast‐based network meta‐analysis (NMA) models. The GFL method penalizes all pairwise differences between treatment effects, resulting in the pooling of treatments that are not sufficiently different. This approach offers an intriguing avenue for potentially mitigating biases in treatment rankings and reducing sparsity in networks. To fit contrast‐based NMA models within the GFL framework, we formulate the models as generalized least squares problems, where the precision matrix depends on the standard error in the data, the estimated between‐study heterogeneity and the correlation between contrasts in multi‐arm studies. By utilizing a Cholesky decomposition of the precision matrix, we linearly transform the data vector and design matrix to frame NMA within the GFL framework. We demonstrate how to construct the GFL penalty such that every pairwise difference is penalized similarly. The model is straightforward to implement in R via the “genlasso” package, and runs instantaneously, contrary to other regularization approaches that are Bayesian. A two‐step GFL‐NMA approach is recommended to obtain measures of uncertainty associated with the (pooled) relative treatment effects. Two simulation studies confirm the GFL approach's ability to pool treatments that have the same (or similar) effects while also revealing when incorrect pooling may occur, and its potential benefits against alternative methods. The novel GFL‐NMA method is successfully applied to a real‐world dataset on diabetes where the standard NMA model was not favored compared to the best‐fitting GFL‐NMA model with AICc selection of the tuning parameter (.


  • Open Access

    What is the optimal management of potentially resectable stage III-N2 NSCLC? Results of a fixed-effects network meta-analysis and economic modelling

    by Matthew Evison, Ross Maconachie, Toby Mercer, Caitlin H. Daly, Nicky J. Welton, Shahzeena Aslam, Doug West, Neal Navani

    Introduction: There is a critical need to understand the optimal treatment regimen in patients with potentially resectable stage III-N2 nonsmall cell lung cancer (NSCLC).Methods: A systematic review of randomised controlled trials was carried out using a literature search including the CDSR, CENTRAL, DARE, HTA, EMBASE and MEDLINE bibliographic databases. Selected trials were used to perform a Bayesian fixed-effects network meta-analysis and economic modelling of treatment regimens relevant to current-day treatment options: chemotherapy plus surgery (CS), chemotherapy plus radiotherapy (CR) and chemoradiotherapy followed by surgery (CRS).Findings: Six trials were prioritised for evidence synthesis. The fixed-effects network meta-analyses demonstrated an improvement in disease-free survival (DFS) for CRSversusCS and CRSversusCR of 0.34 years (95% CI 0.02–0.65) and 0.32 years (95% CI 0.05–0.58) respectively, over a 5-year period. No evidence of effect was observed in overall survival although point estimates favoured CRS. The probabilities that CRS had a greater mean survival time and greater probability of being alive than the reference treatment of CR at 5 years were 89% and 86% respectively. Survival outcomes for CR and CS were essentially equivalent. The economic model calculated that CRS and CS had incremental cost-effectiveness ratios of £19 000/quality-adjusted life-year (QALY) and £78 000/QALY compared to CR. The probability that CRS generated more QALYs than CR and CS was 94%.Interpretation: CRS provides an extended time in a disease-free state leading to improved cost-effectiveness over CR and CS in potentially resectable stage III-N2 NSCLC.


  • Open Access

    Network meta‐interpolation: Effect modification adjustment in network meta‐analysis using subgroup analyses

    by Ofir Harari, Mohsen Soltanifar, Joseph C. Cappelleri, Andre Verhoek, Mario Ouwens, Caitlin Daly, Bart Heeg

    Effect modification (EM) may cause bias in network meta‐analysis (NMA). Existing population adjustment NMA methods use individual patient data to adjust for EM but disregard available subgroup information from aggregated data in the evidence network. Additionally, these methods often rely on the shared effect modification (SEM) assumption. In this paper, we propose Network Meta‐Interpolation (NMI): a method using subgroup analyses to adjust for EM that does not assume SEM. NMI balances effect modifiers across studies by turning treatment effect (TE) estimates at the subgroup‐ and study level into TE and standard errors at EM values common to all studies. In an extensive simulation study, we simulate two evidence networks consisting of four treatments, and assess the impact of departure from the SEM assumption, variable EM correlation across trials, trial sample size and network size. NMI was compared to standard NMA, network meta‐regression (NMR) and Multilevel NMR (ML‐NMR) in terms of estimation accuracy and credible interval (CrI) coverage. In the base case non‐SEM dataset, NMI achieved the highest estimation accuracy with root mean squared error (RMSE) of 0.228, followed by standard NMA (0.241), ML‐NMR (0.447) and NMR (0.541). In the SEM dataset, NMI was again the most accurate method with RMSE of 0.222, followed by ML‐NMR (0.255). CrI coverage followed a similar pattern. NMI's dominance in terms of estimation accuracy and CrI coverage appeared to be consistent across all scenarios. NMI represents an effective option for NMA in the presence of study imbalance and available subgroup data.


  • Open Access

    A non‐parametric approach for jointly combining evidence on progression free and overall survival time in network meta‐analysis

    by Caitlin H. Daly, Ross Maconachie, A. E. Ades, Nicky J. Welton

    Randomised controlled trials of cancer treatments typically report progression free survival (PFS) and overall survival (OS) outcomes. Existing methods to synthesise evidence on PFS and OS either rely on the proportional hazards assumption or make parametric assumptions which may not capture the diverse survival curve shapes across studies and treatments. Furthermore, PFS and OS are not independent; OS is the sum of PFS and post‐progression survival (PPS). Our aim was to develop a non‐parametric approach for jointly synthesising evidence from published Kaplan–Meier survival curves of PFS and OS without assuming proportional hazards. Restricted mean survival times (RMST) are estimated by the area under the survival curves (AUCs) up to a restricted follow‐up time. The correlation between AUCs due to the constraint that OS > PFS is estimated using bootstrap re‐sampling. Network meta‐analysis models are given for RMST for PFS and PPS and ensure that OS = PFS + PPS. Both additive and multiplicative network meta‐analysis models are presented to obtain relative treatment effects as either differences or ratios of RMST. The methods are illustrated with a network meta‐analysis of treatments for stage IIIA‐N2 non‐small cell lung cancer. The approach has implications for health economic models of cancer treatments, which require estimates of the mean time spent in the PFS and PPS health‐states. The methods can be applied to a single time‐to‐event outcome, and so have wide applicability in any field where time‐to‐event outcomes are reported, the proportional hazards assumption is in doubt, and survival curve shapes differ across studies and interventions.


  • Open Access

    Spie charts for quantifying treatment effectiveness and safety in multiple outcome network meta-analysis: A proof-of-concept study

    by Caitlin Daly, Lawrence Mbuagbaw, Lehana Thabane, Sharon E Straus, Jemila S Hamid

    Background: Network meta-analysis (NMA) simultaneously synthesises direct and indirect evidence on the relative efficacy and safety of at least three treatments. A decision maker may use the coherent results of an NMA to determine which treatment is best for a given outcome. However, this evidence must be balanced across multiple outcomes. This study aims to provide a framework that permits the objective integration of the comparative effectiveness and safety of treatments across multiple outcomes.Methods: In the proposed framework, measures of each treatment’s performance are plotted on its own pie chart, superimposed on another pie chart representing the performance of a hypothetical treatment that is the best across all outcomes. This creates a spie chart for each treatment, where the coverage area represents the probability a treatment ranks best overall. The angles of each sector may be adjusted to reflect the importance of each outcome to a decision maker. The framework is illustrated using two published NMA datasets comparing dietary oils and fats and psoriasis treatments. Outcome measures are plotted in terms of the surface under the cumulative ranking curve. The use of the spie chart was contrasted with that of the radar plot.Results: In the NMA comparing the effects of dietary oils and fats on four lipid biomarkers, the ease of incorporating the lipids’ relative importance on spie charts was demonstrated using coefficients from a published risk prediction model on coronary heart disease. Radar plots produced two sets of areas based on the ordering of the lipids on the axes, while the spie chart only produced one set. In the NMA comparing psoriasis treatments, the areas inside spie charts containing both efficacy and safety outcomes masked critical information on the treatments’ comparative safety. Plotting the areas inside spie charts of the efficacy outcomes against measures of the safety outcome facilitated simultaneous comparisons of the treatments’ benefits and harms.Conclusions: The spie chart is more optimal than a radar plot for integrating the comparative effectiveness or safety of a treatment across multiple outcomes. Formal validation in the decision-making context, along with statistical comparisons with other recent approaches are required.